Furthermore, PKCδ inhibition reduces BACE1 expression, Aβ levels, and neuritic plaque formation, and rescues cognitive deficits in an APP Swedish mutations K594N/M595L/presenilin-1 with an exon 9 deletion–transgenic AD mouse model [235]. The gene discussed is APP; the disease is Alzheimer disease.